Pancreatic Cancer Research

ResearcherUniversity of Nebraska Medical CenterNo recent work listed

Vivek Verma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5863-6023; OpenAlex author ID A5071827540. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 6 papers

Papers 9

  1. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. First author DOI 10.1016/j.radonc.2018.11.002↗
  2. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. Co-author DOI 10.1080/0284186x.2019.1631472↗
  3. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic A… First author DOI 10.1097/coc.0000000000000599↗
  4. The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. First author DOI 10.21037/jgo.2019.01.19↗
  5. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. Last author DOI 10.21037/jgo.2019.07.02↗
  6. Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection. First author DOI 10.21037/jgo.2019.09.01↗
  7. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospe… Co-author DOI 10.1016/j.radonc.2016.12.030↗
  8. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. Co-author DOI 10.1186/s13014-017-0798-8↗
  9. Neoadjuvant Therapy for Pancreatic Cancer: Systematic Review of Postoperative Morbidity, Mortality, and Complications. Co-author DOI 10.1097/coc.0000000000000278↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chi H. Lin · 5 shared papers, 2016–2019 · strength 0.43
  2. Chandrakanth Are · 3 shared papers, 2017–2019 · strength 0.24
  3. Dulabh Kaur Monga · 2 shared papers, 2019 · strength 0.19
  4. Rodney E. Wegner · 2 shared papers, 2019 · strength 0.19
  5. Jane L. Meza · 2 shared papers, 2019 · strength 0.17
  6. Jean L. Grem · 2 shared papers, 2019 · strength 0.17
  7. Wei Jiang · 1 shared paper, 2019 · strength 0.12
  8. Bin Sing Teh · 1 shared paper, 2019 · strength 0.12
  9. Jinluan Li · 1 shared paper, 2016 · strength 0.10
  10. Ahmed Khattab · 1 shared paper, 2019 · strength 0.10
  11. Ethan Bernard Ludmir · 1 shared paper, 2019 · strength 0.10
  12. Suzanne Schiffman · 1 shared paper, 2019 · strength 0.09
  13. Shyam J Thakkar · 1 shared paper, 2019 · strength 0.09
  14. Alexander V. Kirichenko · 1 shared paper, 2019 · strength 0.09
  15. Karyn A. Goodman · 1 shared paper, 2019 · strength 0.09
  16. Arya Amini · 1 shared paper, 2019 · strength 0.09
  17. Ashwin Shinde · 1 shared paper, 2019 · strength 0.09
  18. Richard Li · 1 shared paper, 2019 · strength 0.09
  19. Susanne Gray Warner · 1 shared paper, 2019 · strength 0.09
  20. Vincent M. Chung · 1 shared paper, 2019 · strength 0.09
  21. Mustafa Raoof · 1 shared paper, 2019 · strength 0.09
  22. Shuo Wang · 1 shared paper, 2019 · strength 0.09
  23. Lyudmyla Derby Berim · 1 shared paper, 2019 · strength 0.08
  24. Michael Anthony Hollingsworth · 1 shared paper, 2019 · strength 0.08
  25. Dandan Zheng · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.